These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1892033)

  • 41. [Yersinia and infantile gastroenteritis].
    Franzin L; Oderda G
    G Batteriol Virol Immunol; 1989; 82(1-12):108-13. PubMed ID: 2490392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum bactericidal activity for Yersinia enterocolitica in hemodialysis patients: effects of iron overload and deferoxamine.
    Gaughan WJ; Beserab A; Stein HD; Sirota RA; Yudis M
    Am J Kidney Dis; 1992 Feb; 19(2):144-8. PubMed ID: 1739096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A severe case of Yersinia enterocolitica infection in a thalassemic patient.
    Perniola R; Petracca M; De Rinaldis C; Perrone A; Pizzolante M
    Ital J Gastroenterol Hepatol; 1997 Feb; 29(1):82-3. PubMed ID: 9265586
    [No Abstract]   [Full Text] [Related]  

  • 44. [Yersinia enterocolitica: a clinical form, difficult to diagnose].
    Borque Andrés C; González de Dios J; Ramos Lizana J; García Hortelano J
    An Esp Pediatr; 1989 Apr; 30(4):326-8. PubMed ID: 2742245
    [No Abstract]   [Full Text] [Related]  

  • 45. Role of Yersinia enterocolitica.
    Chiesa C; Pacifico L; Midulla M
    Am J Dis Child; 1984 Apr; 138(4):411-2. PubMed ID: 6702799
    [No Abstract]   [Full Text] [Related]  

  • 46. [Yersinia enterocolitica septicemia associated with idiopathic hemochromatosis and deferoxamine therapy. A case].
    Nouel O; Voisin PM; Vaucel J; Dartois-Hoguin M; Le Bris M
    Presse Med; 1991 Oct; 20(31):1494-6. PubMed ID: 1835044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Yersinia enterocolitica septicemia in a thalassemic girl].
    Arístegui J; Gárate J; Ondárroa E; Cos B; Sánchez E; Cisterna R; Delgado A
    An Esp Pediatr; 1985 Jul; 23(1):51-8. PubMed ID: 4062076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Yersinia enterocolitica and thalassemia: more than a chance association].
    Altés J; Antich M; Buades J
    Med Clin (Barc); 1984 Nov; 83(17):735. PubMed ID: 6521535
    [No Abstract]   [Full Text] [Related]  

  • 49. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 50. ["Yersinia pseudotuberculosis" in a case of mesenteric lymphadenitis (author's transl)].
    Ponte MC; Valoria JM; Vega J; Soriano F; Alés JM
    An Esp Pediatr; 1978 Oct; 11(10):709-14. PubMed ID: 365033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease spectrum of Yersinia enterocolitica serogroup 0:3, the predominant cause of human infection in New York City.
    Bottone EJ; Gullans CR; Sierra MF
    Contrib Microbiol Immunol; 1987; 9():56-60. PubMed ID: 3665514
    [No Abstract]   [Full Text] [Related]  

  • 52. Severe Yersinia enterocolitica sepsis after blood transfusion.
    Hoelen DW; Tjan DH; Schouten MA; Dujardin BC; van Zanten AR
    Neth J Med; 2007 Sep; 65(8):301-3. PubMed ID: 17890790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fatal Yersinia enterocolitica sepsis after blood transfusion.
    Wright DC; Selss IF; Vinton KJ; Pierce RN
    Arch Pathol Lab Med; 1985 Nov; 109(11):1040-2. PubMed ID: 3840356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yersinia enterocolitica and transfusion-induced septicemia.
    Brown SE; White SE
    Anesth Analg; 1988 Apr; 67(4):415-7. PubMed ID: 3354879
    [No Abstract]   [Full Text] [Related]  

  • 55. [Mesenteric lymphadenopathy in Yersinia enterocolitica infection].
    Trommer G; Bewer A; Kösling S
    Radiologe; 1998 Jan; 38(1):37-40. PubMed ID: 9530777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Desferrioxamine in hemodialysis as the cause of Yersinia enterocolitica septicemia].
    Waterlot Y; Vanherweghem JL
    Presse Med; 1985 Mar; 14(12):699. PubMed ID: 3157972
    [No Abstract]   [Full Text] [Related]  

  • 57. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 59. Risk factors for sporadic Yersinia enterocolitica infections in Norway: a case-control study.
    Kapperud G; Ostroff SM; Nesbakken T; Hutwagner LC; Bean NH; Lassen J; Tauxe RV
    Contrib Microbiol Immunol; 1995; 13():25-8. PubMed ID: 8833788
    [No Abstract]   [Full Text] [Related]  

  • 60. Current therapy and new approaches to the treatment of thalassemia major.
    Wolfe L; Sallan D; Nathan DG
    Ann N Y Acad Sci; 1985; 445():248-55. PubMed ID: 3860127
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.